Comparing two antibiotics for treating Staphylococcus aureus bloodstream infections
Randomized Controlled Clinical Trial Comparing Treatment With Cloxacillin Versus Benzylpenicillin in Bacteraemia Caused by Penicillin-susceptible Staphylococcus Aureus (PSSA)
This study is testing whether benzylpenicillin works better than cloxacillin for treating bloodstream infections caused by Staphylococcus aureus in adults.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 420 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Region Skane Academic / other |
| Locations | 1 site (Lund) |
| Trial ID | NCT06726395 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to determine whether benzylpenicillin is a more effective treatment than cloxacillin for patients with penicillin-susceptible Staphylococcus aureus bacteraemia. Adult patients over 18 years old diagnosed with this condition will be randomly assigned to receive either benzylpenicillin or cloxacillin after their blood cultures confirm the presence of the bacteria. The study will monitor treatment outcomes, including adverse events and effectiveness, over a specified duration based on the type of infection. The trial is designed to provide insights into optimizing antibiotic therapy for this serious infection.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with penicillin-susceptible Staphylococcus aureus bacteraemia.
Not a fit: Patients with a penicillin allergy or those who are in terminal palliation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment options for patients suffering from Staphylococcus aureus bloodstream infections.
How similar studies have performed: While the comparison of these two antibiotics has not been extensively studied, previous research has indicated the importance of optimizing antibiotic therapy for Staphylococcus aureus infections.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Aged ≥18 with penicillin susceptible S. aureus bacteraemia (PSSA), and able to provide written informed consent. Exclusion Criteria: * allergy to penicillin, * inability to give informed consent, * concomitant growth of other clinically significant bacteria in blood cultures * neutropenia -≥ 96h with prior antibiotics * When the per oral follow up medication can not be flukloxacillin or penicillinV/Amoxicillin (ie prosthetic joint infection) * Patients in terminal palliation, where death is expected within 7 days. * Where the treating physician believes cloxacillin is not a first-line treatment.
Where this trial is running
Lund
- Skånes universitetssjukhus, Region Skåne — Lund, Sweden (Recruiting)
Study contacts
- Principal investigator: Malin Hagstrand Aldman, PhD, MD — Lund University
- Study coordinator: Malin Hagstrand Aldman, PhD
- Email: malin.hagstrand-aldman@skane.se
- Phone: +46768766308
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.